Chronic Aripiprazole and Trazodone Polypharmacy Effects on Systemic and Brain Cholesterol Biosynthesis

• Published in: Biomolecules (Basel, Switzerland) Vol. 13; no. 9; p. 1321
• Main Authors: Korade, Zeljka, Anderson, Allison, Balog, Marta, Tallman, Keri A, Porter, Ned A, Mirnics, Karoly
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 28-08-2023; MDPI
• Subjects: 7-dehydrocholesterol; 7-Dehydrocholesterol reductase; Adrenergic receptors; Alzheimer's disease; Antipsychotics; Aripiprazole; aripiprazole (ARI); Biosynthesis; Brain; Cholesterol; desmosterol; DHCR7; Dosage and administration; Drug dosages; Enzymes; Females; IBA1; Intermediates; Ions; Laboratory animals; Lanosterol; Males; Medical research; Metabolites; Nervous system; Pharmacology, Experimental; Physiological aspects; Polypharmacy; Prescription drugs; Proteins; Serotonin; Sex differences; Sterols; Trazodone; trazodone (TRZ); United States; United States > US
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom13091321

The concurrent use of several medications is a common practice in the treatment of complex psychiatric conditions. One such commonly used combination is aripiprazole (ARI), an antipsychotic, and trazodone (TRZ), an antidepressant. In addition to their effects on dopamine and serotonin systems, both of these compounds are inhibitors of the 7-dehydrocholesterol reductase (DHCR7) enzyme. To evaluate the systemic and nervous system distribution of ARI and TRZ and their effects on cholesterol biosynthesis, adult mice were treated with both ARI and TRZ for 21 days. The parent drugs, their metabolites, and sterols were analyzed in the brain and various organs of mice using LC-MS/MS. The analyses revealed that ARI, TRZ, and their metabolites were readily detectable in the brain and organs, leading to changes in the sterol profile. The levels of medications, their metabolites, and sterols differed across tissues with notable sex differences. Female mice showed higher turnover of ARI and more cholesterol clearance in the brain, with several post-lanosterol intermediates significantly altered. In addition to interfering with sterol biosynthesis, ARI and TRZ exposure led to decreased ionized calcium-binding adaptor molecule 1 (IBA1) and increased DHCR7 protein expression in the cortex. Changes in sterol profile have been also identified in the spleen, liver, and serum, underscoring the systemic effect of ARI and TRZ on sterol biosynthesis. Long-term use of concurrent ARI and TRZ warrants further studies to fully evaluate the lasting consequences of altered sterol biosynthesis on the whole body.